<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Preclinical data suggest that combining the mTOR/<z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor (HIF) inhibitor temsirolimus and the antiangiogenesis antibody bevacizumab may augment antitumor activity as well as resensitize cells to <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>EXPERIMENTAL DESIGN: We initiated a phase I study of bevacizumab and temsirolimus plus liposomal <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> in patients with advanced <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients (N = 136) were enrolled according to a modified 3 + 3 design plus dose expansion in responsive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were breast (n = 29), epithelial ovarian (n = 23), and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (n = 17) </plain></SENT>
<SENT sid="4" pm="."><plain>The median number of prior chemotherapy regimens was four (range: 0-16) </plain></SENT>
<SENT sid="5" pm="."><plain>Grade 3 or higher adverse events (&gt; 5%) included <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, mucositis, <z:e sem="disease" ids="C0549410" disease_type="Disease or Syndrome" abbrv="">hand-foot syndrome</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and <z:mpath ids='MPATH_70'>fistula</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>This regimen led to a 21% (n = 28) stable disease (SD) ≥ 6 months and 21% (n = 29) rate of partial or complete remission [PR/CR; (total SD ≥ 6 months/PR/CR = 42% (n = 57)] </plain></SENT>
<SENT sid="7" pm="."><plain>PR/CR was most common in parotid gland <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (4/6, 67%), metaplastic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (5/12, 42%), endometrial endometrioid <z:mp ids='MP_0002038'>carcinoma</z:mp> (6/15, 40%), and in patients with a PIK3CA mutation and/or a PTEN mutation/loss (11/28, 39%) </plain></SENT>
<SENT sid="8" pm="."><plain>The maximum tolerated dose was liposomal <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> 30 mg/m(2) and bevacizumab 15 mg/kg every three weeks with temsirolimus 25 mg weekly </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Patients tolerated bevacizumab and temsirolimus together with liposomal <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Further evaluation, especially in patients with parotid, metaplastic breast, and endometrial endometrioid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, and in patients with PIK3CA and/or PTEN aberrations is warranted </plain></SENT>
</text></document>